Air pollution may increase risk of Alzheimer's disease and related dementias (ADRD) in the U.S., but the extent of this relationship is unclear. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
We observed a significant association between blood cadmium levels and AD mortality among older adults in the US. 5 key findings →
Participants: 4,064 Evidence: low
Full summary, score breakdown and related studies → Original source
50/100
The restricted use of BDZRs may contribute to dementia prevention in the elderly. 4 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
After the median time of incident TBI, Aβ42/Aβ40 levels remained lower for 9.3 years, and pTau181, NfL, and GFAP remained elevated for 8.5, >13.8, and 12.7 years, respectively. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Type 2 diabetes is an established risk factor for dementia. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
There was no difference in age acceleration between dementia cases and controls. 3 key findings →
Participants: 160 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 275,144 initiators of DPP-4 inhibitors or sulfonylureas, followed for 750,846 person-years, DPP-4 inhibitors were associated with a reduced dementia risk compared with sulfonylureas (4.4 vs. 5.7 events per 1000 person-years; HR 0.77, 95% CI 0.71-0.85). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Among 157 subjects with a mean age of 71.8 (±7.7) included in this study, 76 individuals were stratified as metformin users. 5 key findings →
Participants: 157 Evidence: low
Full summary, score breakdown and related studies → Original source
About 30% to 40% of the general population experiences insomnia symptoms of difficulty initiating or maintaining sleep, and another 10% to 15% of the general population experiences chronic insomnia disorder. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
50/100
Sleep apnea is associated with an increased risk of Parkinson disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
One of the most common medical diseases is metabolic syndrome (MetS), which encompasses diabetes and obesity. 1 key finding →
Participants: 148 Evidence: low
Full summary, score breakdown and related studies → Original source
After adjusting for age, race, and gender, persons with Alzheimer's disease and dementia associated with medical conditions were less likely to be diagnosed with hypertension, diabetes, congestive heart failure, and atrial fibrillation than were controls. 5 key findings →
Participants: 15,013 Evidence: low
Full summary, score breakdown and related studies → Original source
PM2.5 can enter the central nervous system through 2 main pathways, the blood-brain barrier and olfactory neurons. 5 key findings →
Participants: 113 Evidence: low
Full summary, score breakdown and related studies → Original source
The adjusted hazard ratio (HR) of dementia for a 5-μg/m3 increase in NO2 was 1.09 (95% CI, 1.05-1.14); the adjusted HR of dementia for a 1-μg/m3 increase in PM2.5 was 1.10 (1.04-1.17). 5 key findings →
Participants: 447 Evidence: low
Full summary, score breakdown and related studies → Original source
During a median 11.7 years follow-up, 5 905 incident cases of all-cause dementia were identified. 5 key findings →
Participants: 459 Evidence: low
Full summary, score breakdown and related studies → Original source
50/100
A total of 169 patients in Tibet (high altitude) and 310 patients in Beijing (low altitude) were enrolled. 5 key findings →
Participants: 169 Evidence: low
Full summary, score breakdown and related studies → Original source
Compared with Non-Hispanic White (NHW) adults, Non-White adults had a higher incidence of AD-specific (hazard ratio [HR] = 2.05, 95% confidence interval [CI]: 1.21, 3.49) and all-cause dementia (HR = 2.01, 95% CI: 1.36, 2.98). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Participants in the hypertension group with at least 1 ε4 allele showed significantly greater amyloid burden than those with only 1 risk factor or no risk factors. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
After exclusion of the participants who had subsequently refused the medical interview, the 3C Study sample consisted of 3,649 men (39.3%) and 5,645 women, mean age 74.4 years, with a relatively high level of education and income. 4 key findings →
Participants: 9,693 Evidence: low
Full summary, score breakdown and related studies → Original source
The secreted peptide adropin is highly expressed in human brain tissues and correlates with RNA and proteomic risk indicators for dementia. 2 key findings →
Participants: 452 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recent epidemiological and clinico-pathologic data suggest overlaps between Alzheimer disease (AD) and cerebrovascular lesions that may magnify the effect of mild AD pathology and promote progression of cognitive decline or even may precede neuronal damage and dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Severe CAA confers a greater risk of VLs in AD, even within strata of APOE genotype. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Vascular contributions to cognitive impairment and dementia (VCID) are a common cause of cognitive decline, yet limited therapies exist. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
49/100
Among 104 537 individuals, the absolute 10-year risk of Alzheimer disease in 3017 women and men who were carriers of the APOE ɛ44 genotype was, respectively, 7% and 6% at age 60-69 years, 16% and 12% at age 70-79 years, and 24% and 19% at age 80 years and older. 1 key finding →
Participants: 537 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
While all groups are affected by the COVID-19 pandemic, the elderly, underrepresented minorities, and those with underlying medical conditions are at the greatest risk. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Could self-reporting sleep duration become an important tool in the prediction of dementia?
- Diet and nutrition in cardiovascular disease prevention: a scientific statement of the European Association of Preventive Cardiology and the Association of Cardiovascular Nursing & Allied Professions of the European Society of Cardiology
- Depression, cognitive reserve markers, and dementia risk in the general population
- Geographical variation in dementia: systematic review with meta-analysis
- Metformin mitigates dementia risk among individuals with type 2 diabetes
- Aging and Hearing Health: The Life-course Approach
- Omega-3 fatty acids and dementia
- Multidomain lifestyle interventions for the risk reduction of cognitive impairment and dementia: A systematic review and meta-analysis
- Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study
- Risk factors for aspiration pneumonia in frail older people: a systematic literature review
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →